Skip to main content
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:

    Reviewed by Dr Sarah Mitchell, PhD · Editorial Board

    GLP-1 Centre

    GLP-1 medicines — side-effect literacy

    The side-effect profile of semaglutide, tirzepatide, and liraglutide is broadly similar. Most users get some gastrointestinal effects during dose escalation; most settle. A small number have less-common or rare adverse events that need prompt attention. This page is plain-English literacy — read the Patient Information Leaflet that comes with your prescription for the full official list.

    Common side effects — most users, especially at start

    • Nausea — most commonly reported. Usually worst in the first few days after a dose increase and settles over a week or two.
    • Vomiting — sometimes follows nausea, particularly with larger meals or fatty foods.
    • Diarrhoea — common early; usually self-limiting.
    • Constipation — equally common in some users; hydration and fibre help.
    • Reduced appetite, early satiety — the mechanism of action manifesting; not technically a side effect.
    • Fatigue — often related to reduced calorie intake during the first weeks; usually improves.
    • Injection-site reactions — minor redness or itching; rotating injection sites helps.

    Slow titration is the single biggest tool for managing these. If a dose step is hard, talk to your prescriber about holding at the current dose for longer rather than pushing through.

    Less-common but documented effects

    • Gallbladder issues — gallstones and cholecystitis are documented at elevated rates. Right-upper-quadrant abdominal pain after meals warrants assessment.
    • Hair shedding — anecdotally reported, often associated with rapid weight loss generally; usually transient.
    • Lean-mass loss — alongside fat loss; resistance training and adequate protein intake help.
    • Vivid dreams or insomnia — reported anecdotally; mechanism not well characterised.
    • Heart rate increase — small mean increase reported in trials.

    Rare but serious — seek urgent advice

    • Acute pancreatitis — severe persistent abdominal pain, often radiating to the back, sometimes with nausea/vomiting. Call NHS 111 or 999 if severe.
    • Severe allergic reaction (anaphylaxis) — facial / throat swelling, difficulty breathing. Call 999.
    • Diabetic retinopathy progression in people with type 2 diabetes — rapid glucose drop can transiently worsen retinopathy. Ophthalmology review is part of standard care for this group.
    • Severe hypoglycaemia — uncommon on GLP-1 monotherapy but elevated risk if combined with sulfonylureas or insulin.
    • Suicidal thoughts — investigated as a potential signal; current regulatory position is that no causal link has been established, but if you experience new or worsening psychiatric symptoms while on a GLP-1 medicine, contact your prescriber and consider stopping. NHS 111 / 999 for acute risk.

    What to do if you suspect a side effect

    1. Routine: contact your prescriber. Adjust dose, timing, or stop per their advice.
    2. Urgent but non-emergency: NHS 111.
    3. Emergency: 999.
    4. Report: via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or the Yellow Card app. Patient and clinician reports are both welcome. See our Yellow Card page.

    Side-effect questions for your prescriber

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Which side effects are most likely for me given my history and dose?
    • How should I manage nausea or vomiting — practical tips and when to escalate?
    • What are the warning signs that mean I should contact you immediately versus 111 versus 999?
    • If a side effect appears, do we hold the dose, drop back, or stop?
    • Are there interactions with my other medicines I should be alert for?
    • How do you handle Yellow Card reporting — do you report, or should I?

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    Related